 | • レポートコード：QFJ1-4847 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、強皮症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリン類似体、カルシウムチャネル遮断薬、鎮痛薬、その他）、用途別市場規模（全身、局所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・強皮症治療薬の市場動向 ・企業の競争状況、市場シェア ・強皮症治療薬の種類別市場規模と予測2016-2027（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリン類似体、カルシウムチャネル遮断薬、鎮痛薬、その他） ・強皮症治療薬の用途別市場規模と予測2016-2027（全身、局所） ・強皮症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・強皮症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・強皮症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・強皮症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・強皮症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（F. Hoffmann-La Roche AG、Bristol-Myers Squibb Company、Celgene Corporation、Argentis Pharmaceuticals, LLC、Bayer AG、Boehringer Ingelheim International GmbH、Akashi Therapeutics、Prometic Life Sciences, Inc.、Emerald Health Pharmaceuticals、Kadmon Holdings, Inc.、Seattle Genetics, Inc.、Cytori Therapeutics, Inc.、Fibrocell Science, Inc.、Chemomab、Corbus Pharmaceuticals Holdings, Inc.、Genkyotex） ・結論 |
Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.
The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.
Market Analysis and Insights: Global Scleroderma Therapeutics Market
The global Scleroderma Therapeutics market size is projected to reach US$ 1827.1 million by 2027, from US$ 1402.3 million in 2020, at a CAGR of 3.4% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Scleroderma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Scleroderma Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Scleroderma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Scleroderma Therapeutics market.
Global Scleroderma Therapeutics Scope and Market Size
Scleroderma Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Scleroderma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Immunosuppressors
Phosphodiesterase 5 Inhibitors – PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others
Segment by Application
Systemic
Localized
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunosuppressors
1.2.3 Phosphodiesterase 5 Inhibitors – PHA
1.2.4 Endothelin Receptor Antagonists
1.2.5 Prostacyclin Analogues
1.2.6 Calcium Channel Blockers
1.2.7 Analgesics
1.2.8 Others
1.3 Market by Application
1.3.1 Global Scleroderma Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Systemic
1.3.3 Localized
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Scleroderma Therapeutics Market Perspective (2016-2027)
2.2 Scleroderma Therapeutics Growth Trends by Regions
2.2.1 Scleroderma Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Scleroderma Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Scleroderma Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Scleroderma Therapeutics Industry Dynamic
2.3.1 Scleroderma Therapeutics Market Trends
2.3.2 Scleroderma Therapeutics Market Drivers
2.3.3 Scleroderma Therapeutics Market Challenges
2.3.4 Scleroderma Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Scleroderma Therapeutics Players by Revenue
3.1.1 Global Top Scleroderma Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Scleroderma Therapeutics Revenue
3.4 Global Scleroderma Therapeutics Market Concentration Ratio
3.4.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2020
3.5 Scleroderma Therapeutics Key Players Head office and Area Served
3.6 Key Players Scleroderma Therapeutics Product Solution and Service
3.7 Date of Enter into Scleroderma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Scleroderma Therapeutics Breakdown Data by Type
4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2022-2027)
5 Scleroderma Therapeutics Breakdown Data by Application
5.1 Global Scleroderma Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Scleroderma Therapeutics Market Size (2016-2027)
6.2 North America Scleroderma Therapeutics Market Size by Type
6.2.1 North America Scleroderma Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Scleroderma Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Scleroderma Therapeutics Market Size by Type (2016-2027)
6.3 North America Scleroderma Therapeutics Market Size by Application
6.3.1 North America Scleroderma Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Scleroderma Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Scleroderma Therapeutics Market Size by Application (2016-2027)
6.4 North America Scleroderma Therapeutics Market Size by Country
6.4.1 North America Scleroderma Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Scleroderma Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Scleroderma Therapeutics Market Size (2016-2027)
7.2 Europe Scleroderma Therapeutics Market Size by Type
7.2.1 Europe Scleroderma Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Scleroderma Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Scleroderma Therapeutics Market Size by Type (2016-2027)
7.3 Europe Scleroderma Therapeutics Market Size by Application
7.3.1 Europe Scleroderma Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Scleroderma Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Scleroderma Therapeutics Market Size by Application (2016-2027)
7.4 Europe Scleroderma Therapeutics Market Size by Country
7.4.1 Europe Scleroderma Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Scleroderma Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Scleroderma Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Scleroderma Therapeutics Market Size by Type
8.2.1 Asia-Pacific Scleroderma Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Scleroderma Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Scleroderma Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Scleroderma Therapeutics Market Size by Application
8.3.1 Asia-Pacific Scleroderma Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Scleroderma Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Scleroderma Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Scleroderma Therapeutics Market Size by Region
8.4.1 Asia-Pacific Scleroderma Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Scleroderma Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Scleroderma Therapeutics Market Size (2016-2027)
9.2 Latin America Scleroderma Therapeutics Market Size by Type
9.2.1 Latin America Scleroderma Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Scleroderma Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Scleroderma Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Scleroderma Therapeutics Market Size by Application
9.3.1 Latin America Scleroderma Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Scleroderma Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Scleroderma Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Scleroderma Therapeutics Market Size by Country
9.4.1 Latin America Scleroderma Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Scleroderma Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Scleroderma Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Scleroderma Therapeutics Market Size by Type
10.2.1 Middle East & Africa Scleroderma Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Scleroderma Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Scleroderma Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Scleroderma Therapeutics Market Size by Application
10.3.1 Middle East & Africa Scleroderma Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Scleroderma Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Scleroderma Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Scleroderma Therapeutics Market Size by Country
10.4.1 Middle East & Africa Scleroderma Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Scleroderma Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 F. Hoffmann-La Roche AG Company Details
11.1.2 F. Hoffmann-La Roche AG Business Overview
11.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction
11.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2016-2021)
11.1.5 F. Hoffmann-La Roche AG Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2016-2021)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Details
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Scleroderma Therapeutics Introduction
11.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2016-2021)
11.3.5 Celgene Corporation Recent Development
11.4 Argentis Pharmaceuticals, LLC
11.4.1 Argentis Pharmaceuticals, LLC Company Details
11.4.2 Argentis Pharmaceuticals, LLC Business Overview
11.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction
11.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2016-2021)
11.4.5 Argentis Pharmaceuticals, LLC Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Scleroderma Therapeutics Introduction
11.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2016-2021)
11.5.5 Bayer AG Recent Development
11.6 Boehringer Ingelheim International GmbH
11.6.1 Boehringer Ingelheim International GmbH Company Details
11.6.2 Boehringer Ingelheim International GmbH Business Overview
11.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction
11.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2016-2021)
11.6.5 Boehringer Ingelheim International GmbH Recent Development
11.7 Akashi Therapeutics
11.7.1 Akashi Therapeutics Company Details
11.7.2 Akashi Therapeutics Business Overview
11.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction
11.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2016-2021)
11.7.5 Akashi Therapeutics Recent Development
11.8 Prometic Life Sciences, Inc.
11.8.1 Prometic Life Sciences, Inc. Company Details
11.8.2 Prometic Life Sciences, Inc. Business Overview
11.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction
11.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021)
11.8.5 Prometic Life Sciences, Inc. Recent Development
11.9 Emerald Health Pharmaceuticals
11.9.1 Emerald Health Pharmaceuticals Company Details
11.9.2 Emerald Health Pharmaceuticals Business Overview
11.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction
11.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2016-2021)
11.9.5 Emerald Health Pharmaceuticals Recent Development
11.10 Kadmon Holdings, Inc.
11.10.1 Kadmon Holdings, Inc. Company Details
11.10.2 Kadmon Holdings, Inc. Business Overview
11.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction
11.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021)
11.10.5 Kadmon Holdings, Inc. Recent Development
11.11 Seattle Genetics, Inc.
11.11.1 Seattle Genetics, Inc. Company Details
11.11.2 Seattle Genetics, Inc. Business Overview
11.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction
11.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021)
11.11.5 Seattle Genetics, Inc. Recent Development
11.12 Cytori Therapeutics, Inc.
11.12.1 Cytori Therapeutics, Inc. Company Details
11.12.2 Cytori Therapeutics, Inc. Business Overview
11.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction
11.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021)
11.12.5 Cytori Therapeutics, Inc. Recent Development
11.13 Fibrocell Science, Inc.
11.13.1 Fibrocell Science, Inc. Company Details
11.13.2 Fibrocell Science, Inc. Business Overview
11.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction
11.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021)
11.13.5 Fibrocell Science, Inc. Recent Development
11.14 Chemomab
11.14.1 Chemomab Company Details
11.14.2 Chemomab Business Overview
11.14.3 Chemomab Scleroderma Therapeutics Introduction
11.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2016-2021)
11.14.5 Chemomab Recent Development
11.15 Corbus Pharmaceuticals Holdings, Inc.
11.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Details
11.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview
11.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction
11.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021)
11.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Development
11.16 Genkyotex
11.16.1 Genkyotex Company Details
11.16.2 Genkyotex Business Overview
11.16.3 Genkyotex Scleroderma Therapeutics Introduction
11.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2016-2021)
11.16.5 Genkyotex Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Scleroderma Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunosuppressors
Table 3. Key Players of Phosphodiesterase 5 Inhibitors - PHA
Table 4. Key Players of Endothelin Receptor Antagonists
Table 5. Key Players of Prostacyclin Analogues
Table 6. Key Players of Calcium Channel Blockers
Table 7. Key Players of Analgesics
Table 8. Key Players of Others
Table 9. Global Scleroderma Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Scleroderma Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Scleroderma Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Scleroderma Therapeutics Market Share by Regions (2016-2021)
Table 13. Global Scleroderma Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Scleroderma Therapeutics Market Share by Regions (2022-2027)
Table 15. Scleroderma Therapeutics Market Trends
Table 16. Scleroderma Therapeutics Market Drivers
Table 17. Scleroderma Therapeutics Market Challenges
Table 18. Scleroderma Therapeutics Market Restraints
Table 19. Global Scleroderma Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Scleroderma Therapeutics Market Share by Players (2016-2021)
Table 21. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2020)
Table 22. Ranking of Global Top Scleroderma Therapeutics Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Scleroderma Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Scleroderma Therapeutics Product Solution and Service
Table 26. Date of Enter into Scleroderma Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Scleroderma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Scleroderma Therapeutics Revenue Market Share by Type (2016-2021)
Table 30. Global Scleroderma Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Scleroderma Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Scleroderma Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Scleroderma Therapeutics Revenue Market Share by Application (2016-2021)
Table 34. Global Scleroderma Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Scleroderma Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Scleroderma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Scleroderma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Scleroderma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Scleroderma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Scleroderma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Scleroderma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Scleroderma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Scleroderma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Scleroderma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Scleroderma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Scleroderma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Scleroderma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Scleroderma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Scleroderma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Scleroderma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Scleroderma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Scleroderma Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Scleroderma Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Scleroderma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Scleroderma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Scleroderma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Scleroderma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Scleroderma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Scleroderma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Scleroderma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Scleroderma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Scleroderma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Scleroderma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Scleroderma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Scleroderma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 66. F. Hoffmann-La Roche AG Company Details
Table 67. F. Hoffmann-La Roche AG Business Overview
Table 68. F. Hoffmann-La Roche AG Scleroderma Therapeutics Product
Table 69. F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 70. F. Hoffmann-La Roche AG Recent Development
Table 71. Bristol-Myers Squibb Company Company Details
Table 72. Bristol-Myers Squibb Company Business Overview
Table 73. Bristol-Myers Squibb Company Scleroderma Therapeutics Product
Table 74. Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Bristol-Myers Squibb Company Recent Development
Table 76. Celgene Corporation Company Details
Table 77. Celgene Corporation Business Overview
Table 78. Celgene Corporation Scleroderma Therapeutics Product
Table 79. Celgene Corporation Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Celgene Corporation Recent Development
Table 81. Argentis Pharmaceuticals, LLC Company Details
Table 82. Argentis Pharmaceuticals, LLC Business Overview
Table 83. Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Product
Table 84. Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Argentis Pharmaceuticals, LLC Recent Development
Table 86. Bayer AG Company Details
Table 87. Bayer AG Business Overview
Table 88. Bayer AG Scleroderma Therapeutics Product
Table 89. Bayer AG Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 90. Bayer AG Recent Development
Table 91. Boehringer Ingelheim International GmbH Company Details
Table 92. Boehringer Ingelheim International GmbH Business Overview
Table 93. Boehringer Ingelheim International GmbH Scleroderma Therapeutics Product
Table 94. Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Boehringer Ingelheim International GmbH Recent Development
Table 96. Akashi Therapeutics Company Details
Table 97. Akashi Therapeutics Business Overview
Table 98. Akashi Therapeutics Scleroderma Therapeutics Product
Table 99. Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Akashi Therapeutics Recent Development
Table 101. Prometic Life Sciences, Inc. Company Details
Table 102. Prometic Life Sciences, Inc. Business Overview
Table 103. Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Prometic Life Sciences, Inc. Recent Development
Table 105. Emerald Health Pharmaceuticals Company Details
Table 106. Emerald Health Pharmaceuticals Business Overview
Table 107. Emerald Health Pharmaceuticals Scleroderma Therapeutics Product
Table 108. Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 109. Emerald Health Pharmaceuticals Recent Development
Table 110. Kadmon Holdings, Inc. Company Details
Table 111. Kadmon Holdings, Inc. Business Overview
Table 112. Kadmon Holdings, Inc. Scleroderma Therapeutics Product
Table 113. Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 114. Kadmon Holdings, Inc. Recent Development
Table 115. Seattle Genetics, Inc. Company Details
Table 116. Seattle Genetics, Inc. Business Overview
Table 117. Seattle Genetics, Inc. Scleroderma Therapeutics Product
Table 118. Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 119. Seattle Genetics, Inc. Recent Development
Table 120. Cytori Therapeutics, Inc. Company Details
Table 121. Cytori Therapeutics, Inc. Business Overview
Table 122. Cytori Therapeutics, Inc. Scleroderma Therapeutics Product
Table 123. Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 124. Cytori Therapeutics, Inc. Recent Development
Table 125. Fibrocell Science, Inc. Company Details
Table 126. Fibrocell Science, Inc. Business Overview
Table 127. Fibrocell Science, Inc. Scleroderma Therapeutics Product
Table 128. Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 129. Fibrocell Science, Inc. Recent Development
Table 130. Chemomab Company Details
Table 131. Chemomab Business Overview
Table 132. Chemomab Scleroderma Therapeutics Product
Table 133. Chemomab Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 134. Chemomab Recent Development
Table 135. Corbus Pharmaceuticals Holdings, Inc. Company Details
Table 136. Corbus Pharmaceuticals Holdings, Inc. Business Overview
Table 137. Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Product
Table 138. Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 139. Corbus Pharmaceuticals Holdings, Inc. Recent Development
Table 140. Genkyotex Company Details
Table 141. Genkyotex Business Overview
Table 142. Genkyotex Scleroderma Therapeutics Product
Table 143. Genkyotex Revenue in Scleroderma Therapeutics Business (2016-2021) & (US$ Million)
Table 144. Genkyotex Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Scleroderma Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Immunosuppressors Features
Figure 3. Phosphodiesterase 5 Inhibitors - PHA Features
Figure 4. Endothelin Receptor Antagonists Features
Figure 5. Prostacyclin Analogues Features
Figure 6. Calcium Channel Blockers Features
Figure 7. Analgesics Features
Figure 8. Others Features
Figure 9. Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2027
Figure 10. Systemic Case Studies
Figure 11. Localized Case Studies
Figure 12. Scleroderma Therapeutics Report Years Considered
Figure 13. Global Scleroderma Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Scleroderma Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Scleroderma Therapeutics Market Share by Regions: 2020 VS 2027
Figure 16. Global Scleroderma Therapeutics Market Share by Regions (2022-2027)
Figure 17. Global Scleroderma Therapeutics Market Share by Players in 2020
Figure 18. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Scleroderma Therapeutics Revenue in 2020
Figure 20. Global Scleroderma Therapeutics Revenue Market Share by Type (2016-2021)
Figure 21. Global Scleroderma Therapeutics Revenue Market Share by Type (2022-2027)
Figure 22. North America Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Scleroderma Therapeutics Market Share by Type (2016-2027)
Figure 24. North America Scleroderma Therapeutics Market Share by Application (2016-2027)
Figure 25. North America Scleroderma Therapeutics Market Share by Country (2016-2027)
Figure 26. United States Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Scleroderma Therapeutics Market Share by Type (2016-2027)
Figure 30. Europe Scleroderma Therapeutics Market Share by Application (2016-2027)
Figure 31. Europe Scleroderma Therapeutics Market Share by Country (2016-2027)
Figure 32. Germany Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Scleroderma Therapeutics Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Scleroderma Therapeutics Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Scleroderma Therapeutics Market Share by Region (2016-2027)
Figure 42. China Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Scleroderma Therapeutics Market Share by Type (2016-2027)
Figure 50. Latin America Scleroderma Therapeutics Market Share by Application (2016-2027)
Figure 51. Latin America Scleroderma Therapeutics Market Share by Country (2016-2027)
Figure 52. Mexico Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Scleroderma Therapeutics Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Scleroderma Therapeutics Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Scleroderma Therapeutics Market Share by Country (2016-2027)
Figure 58. Turkey Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Scleroderma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 63. Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 64. Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 65. Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 66. Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 67. Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 68. Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 69. Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 70. Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 71. Seattle Genetics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 72. Cytori Therapeutics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 73. Fibrocell Science, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 74. Chemomab Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 75. Corbus Pharmaceuticals Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 76. Genkyotex Revenue Growth Rate in Scleroderma Therapeutics Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
世界の全身性強皮症治療市場規模・現状・予測（2021年-2027年） Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connecti…- 世界の全身性強皮症治療薬市場規模・現状・予測（2021年-2027年） Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connecti…
- 強皮症治療薬のグローバル市場：規模・現状・予測2019-2025 Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.The m…
- 強皮症治療薬のグローバル市場：規模・現状・予測2019-2025 Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.The m…
- 強皮症の診断および治療のグローバル市場調査 2019年 The global Scleroderma Diagnostics and Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Scleroderma Diagnostics and Therapeutics volume and value at global level, regional level and comp…